MYGN — Myriad Genetics Cashflow Statement
0.000.00%
Last trade - 00:00- $428.27m
- $398.57m
- $824.50m
Annual cashflow statement for Myriad Genetics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -27.2 | -112 | -263 | -127 | -366 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -106 | 85.3 | 83.8 | 115 | 333 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 120 | -102 | 10.7 | -54.4 | -19.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 18.2 | -106 | -111 | -8.7 | 1.8 |
| Capital Expenditures | -18 | -45.3 | -73.3 | -29.7 | -27.4 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 292 | -32.2 | 105 | 17.8 | 0 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 274 | -77.5 | 31.9 | -11.9 | -27.4 |
| Financing Cash Flow Items | -4.5 | -3.7 | -1.7 | 0 | -16.1 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -151 | -8 | 153 | -7.4 | 64.2 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 141 | -192 | 74.5 | -29 | 39.4 |